Compare NEON & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEON | OTLK |
|---|---|---|
| Founded | 1997 | 2010 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.5M | 29.2M |
| IPO Year | 1994 | 2016 |
| Metric | NEON | OTLK |
|---|---|---|
| Price | $1.80 | $0.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $6.00 | $2.50 |
| AVG Volume (30 Days) | 96.9K | ★ 4.2M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 37.88 | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | $3,108,000.00 | ★ $8,146,123.00 |
| Revenue This Year | $72.74 | $1,430.98 |
| Revenue Next Year | $28.94 | $173.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.27 | $0.16 |
| 52 Week High | $29.90 | $3.39 |
| Indicator | NEON | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 57.55 | 59.76 |
| Support Level | $1.66 | $0.17 |
| Resistance Level | $1.91 | $0.39 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 67.14 | 65.24 |
Neonode Inc provides software solutions for machine perception that feature machine learning algorithms to detect and track persons and objects in video streams from cameras and other types of imagers. Its machine perception solutions are based on the MultiSensing technology platform. The company also offers optical sensing solutions for contactless touch and gesture sensing. It markets and sells its solutions mainly to customers in the automotive sector, along with other markets such as office equipment, industrial automation, medical, military, and avionics. Geographically, the company operates in Japan, South Korea, Germany, Sweden, China, and other regions, with a majority of its revenue generated from Japan.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.